Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Radiation.

Mayo Clinic, Rochester, MN, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Rochester, MN
Treatments:Chemotherapy, RadiationHospital:Mayo Clinic
Drugs:Journal:Link
Date:Aug 2006

Description:

Patients: This phase III study involved 401 patients with newly diagnosed glioblastoma multiforme. The median age was 56 years, and the majority (over 60%) were men.

Treatment: The patients were divided into four different treatment ‘arms’. Arm A received the chemotherapy drug carmustine and standard radiation therapy; Arm B received carmustine and accelerated radiation therapy; Arm C received carmustine, cisplatin, and standard radiation therapy; Arm D received carmustine, cisplatin, and accelerated radiation therapy.

Toxicity: The most common toxicities were neutropenia, thrombocytopenia, nausea, vomiting, lethargy, headache, neurosensory changes, hearing loss, alopecia, anorexia, and skin reactions. One death due to neurocortical toxicity occurred. Four patients died from infections related to treatment.

Results: The median survival time for patients that received carmustine and standard radiation therapy (Arm A) was 10.4 months. For patients that received carmustine and accelerated radiation therapy (Arm B), the median survival time was 10.1 months. Patients that received carmustine, cisplatin, and standard radiation therapy (Arm C) had a median survival time of 12.0 months, and those in Arm D (received carmustine, cisplatin, and accelerated radiation therapy) had a median survival time of 11.6 months.

Correspondence: Jan Buckner, M.D.





Back